Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers

Journal of the National Cancer Institute

Volumn 103, Issue 2, 2011, Pages 105-116

  Ramus, Susan J ^a   Kartsonaki, Christiana ^b   Gayther, Simon A ^a   Pharoah, Paul D P ^c   Sinilnikova, Olga M ^d   Beesley, Jonathan ^e   Chen, Xiaoqing ^e   McGuffog, Lesley ^b   Healey, Sue ^e   Couch, Fergus J ^f   Wang, Xianshu ^f   Fredericksen, Zachary ^g   Peterlongo, Paolo ^h   Manoukian, Siranoush ^h   Peissel, Bernard ^h   Zaffaroni, Daniela ^h   Roversi, Gaia ^h   Barile, Monica ⁱ   Viel, Alessandra ^h   Allavena, Anna ^j   Ottini, Laura ^k   Papi, Laura ^l   Gismondi, Viviana ^m   Capra, Fabio ⁿ   Radice, Paolo ^a   Greene, Mark H ^o   Mai, Phuong L ^o   Andrulis, Irene L ^p   Glendon, Gord ^q   Ozcelik, Hilmi ^r   Thomassen, Mads ^s   Gerdes, Anne Marie ^r,s   Kruse, Torben A ^t   Cruger, Dorthe ^t   Jensen, Uffe Birk ^u   Caligo, Maria Adelaide ^v   Olsson, Hkan ^v   Kristoffersson, Ulf ^v   Lindblom, Annika ^w   Arver, Brita ^x   Karlsson, Per ^y   Stenmark Askmalm, Marie ^y   Borg, Ake ^a   Neuhausen, Susan L ^f   Ding, Yuan Chun ^f   Nathanson, Katherine L ^z   Domchek, Susan M ^z   Jakubowska, Anna ^aa   Lubiński, Jan ^aa   Huzarski, Tomasz ^aa   Byrski, Tomasz ^aa   Gronwald, Jacek ^aa   Górski, Bohdan ^aa   Cybulski, Cezary ^aa   Dbniak, Tadeusz ^aa   Osorio, Ana ^ab   Durán, Mercedes ^ac   Tejada, Maria Isabel ^ad   Benítez, Javier ^ae   Hamann, Ute ^af   Rookus, Matti A ^ag   Verhoef, Senno ^ah   Tilanus Linthorst, Madeleine A ^af   Vreeswijk, Maaike P ^ai   Bodmer, Danielle ^aj   Ausems, Margreet G E M ^aj   Van Os, Theo A ^ak   Asperen, Christi J ^al   Blok, Marinus J ^am   Meijers Heijboer, Hanne E J ^an   Peock, Susan ^ao   Cook, Margaret ^ap   Oliver, Clare ^aq   Frost, Debra ^b   Dunning, Alison M ^ar   Evans, D Gareth ^as   Eeles, Ros ^at   Pichert, Gabriella ^au   Cole, Trevor ^av   Hodgson, Shirley ^aw   Brewer, Carole ^ax   Morrison, Patrick J ^ay   Porteous, Mary ^az   Kennedy, M John ^ba   Rogers, Mark T ^bb   Side, Lucy E ^bc   Donaldson, Alan ^bd   Gregory, Helen ^be   Godwin, Andrew ^bf   Stoppa Lyonnet, Dominique ^bg   Moncoutier, Virginie ^bh   Castera, Laurent ^bi   Mazoyer, Sylvie ^bj   Barjhoux, Laure ^bk   Bonadona, Valérie ^bk   Leroux, Dominique ^bl   Faivre, Laurence ^bm   Lidereau, Rosette ^bn   Nogues, Catherine ^bo   Bignon, Yves Jean ^bp   Prieur, Fabienne ^bq   Collonge Rame, Marie Agns ^br   Venat Bouvet, Laurence ^bs   Fert Ferrer, Sandra ^bt   Miron, Alex ^bu   Buys, Saundra S ^bv   Hopper, John L ^u   Daly, Mary B ^bw   John, Esther M ^bx   Terry, Mary Beth ^by   Goldgar, David ^bz   Hansen, Thomas V O ^ca   Jønson, Lars ^cb   Ejlertsen, Bent ^cc   Agnarsson, Bjarni A ^cd   Offit, Kenneth ^ce   Kirchhoff, Tomas ^cf   Vijai, Joseph ^cg   Dutra Clarke, Ana V C ^ch   Przybylo, Jennifer A ^ci   Montagna, Marco ^cj   Casella, Cinzia ^ck   Imyanitov, Evgeny N ^cl   Janavicius, Ramunas ^cm   Blanco, Ignacio ^cn   Lázaro, Conxi ^co   Moysich, Kirsten B ^cp   Karlan, Beth Y ^cq   Gross, Jenny ^cr   Beattie, Mary S ^cs   Schmutzler, Rita ^cs   Wappenschmidt, Barbara ^ct   Meindl, Alfons ^cu   Ruehl, Ina ^a   Fiebig, Britta ^a   Sutter, Christian ^b   Arnold, Norbert ^c,d   Deissler, Helmut ^f   Varon Mateeva, Raymonda ^g   Kast, Karin ^g   Niederacher, Dieter ^b   Gadzicki, Dorothea ^e   Caldes, Trinidad ^e   De La Hoya, Miguel ^g   Nevanlinna, Heli ^d   Aittomäki, Kristiina ^a   Simard, Jacques ^a   Soucy, Penny ^a   Spurdle, Amanda B ^e   Holland, Helene ^e   Chenevix Trench, Georgia ^e   Easton, Douglas F ^b   Antoniou, Antonis C ^b   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d HOSPICES CIVILS DE LYON   (France)

^e QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^f Department of Laboratory Medicine and Pathology ^*  (United States)

^g MAYO CLINIC   (United States)

^h NATIONAL CANCER INSTITUTE   (Italy)

ⁱ FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^j EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^k CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^l UNIVERSITY OF TURIN   (Italy)

^m SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁿ UNIVERSITY OF FLORENCE   (Italy)

^o UNIVERSITY OF GENOA   (Italy)

^p IRCCS Istituto Nazionale per la Ricerca sul Cancro ^*  (Italy)

^q NATIONAL CANCER INSTITUTE   (United States)

^r MOUNT SINAI HOSPITAL   (Canada)

^s CANCER CARE ONTARIO   (Canada)

^t ODENSE UNIVERSITY HOSPITAL   (Denmark)

^u University of Copenhagen   (Denmark)

^v LILLEBAELT HOSPITAL   (Denmark)

^w AARHUS UNIVERSITY HOSPITAL   (Denmark)

^x UNIVERSITY HOSPITAL OF PISA   (Italy)

^y LUND UNIVERSITY   (Sweden)

^z KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^aa SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^ab LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^ac CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^ad UNIVERSITY OF PENNSYLVANIA   (United States)

^ae POMERANIAN MEDICAL UNIVERSITY   (Poland)

^af Structural Biology and Biocomputing Programme   (Spain)

^ag UNIVERSITY OF VALLADOLID   (Spain)

^ah HOSPITAL DE CRUCES   (Spain)

^ai GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^aj NETHERLANDS CANCER INSTITUTE   (Netherlands)

^ak ERASMUS MEDICAL CENTER   (Netherlands)

^al LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^am RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^an UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^ao ACADEMIC MEDICAL CENTER   (Netherlands)

^ap MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^aq VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^ar UNIVERSITY OF MANCHESTER   (United Kingdom)

^as INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^at GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^au BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^av ST GEORGE S HOSPITAL   (United Kingdom)

^aw ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^ax BELFAST CITY HOSPITAL   (United Kingdom)

^ay WESTERN GENERAL HOSPITAL   (United Kingdom)

^az ST JAMES S HOSPITAL   (Ireland)

^ba UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^bb GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^bc ST MICHAEL'S HOSPITAL   (United Kingdom)

^bd UNIVERSITY OF ABERDEEN   (United Kingdom)

^be FOX CHASE CANCER CENTER   (United States)

^bf INSERM   (France)

^bg UNIVERSITÉ DE LYON   (France)

^bh UNIVERSITÉ LYON 1   (France)

^bi GRENOBLE UNIVERSITY HOSPITAL   (France)

^bj DIJON UNIVERSITY HOSPITAL   (France)

^bk CENTRE RENÉ HUGUENIN   (France)

^bl CENTRE JEAN PERRIN   (France)

^bm UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^bn UNIVERSITY HOSPITAL OF BESANÇON   (France)

^bo DUPUYTREN UNIVERSITY HOSPITAL   (France)

^bp CENTRE HOSPITALIER DE CHAMBÉRY   (France)

^bq DANA FARBER CANCER INSTITUTE   (United States)

^br UNIVERSITY OF UTAH   (United States)

^bs UNIVERSITY OF MELBOURNE   (Australia)

^bt STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^bu Department of Medicine   (United States)

^bv UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^bw LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^bx MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^by VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^bz N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^ca VILNIUS UNIVERSITY   (Lithuania)

^cb CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^cc ROSWELL PARK CANCER INSTITUTE   (United States)

^cd CEDARS SINAI MEDICAL CENTER   (United States)

^ce UNIVERSITY OF CALIFORNIA   (United States)

^cf Centre of Familial Breast and Ovarian Cancer   (United States)

^cg UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^ch TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^ci UNIVERSITY OF MUNICH   (Germany)

^cj UNIVERSITY OF REGENSBURG   (Germany)

^ck UNIVERSITY OF HEIDELBERG   (Germany)

^cl UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^cm UNIVERSITY HOSPITAL ULM   (Germany)

^cn CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^co UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^cp UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^cq HANNOVER MEDICAL SCHOOL   (Germany)

^cr HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^cs HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^ct LAVAL UNIVERSITY   (Canada)

^cu UNIVERSITY OF CAMBRIDGE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CHROMOSOME 9P; FEMALE; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 79251507591     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq494     Document Type: Article

References (43)

1. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994; 266(5182):66-71. (Pubitemid 24345325)
2. Wooster R, Bignell G, Lancaster J, et al. Identifcation of the breast cancer susceptibility gene BRCA2. Nature. 1995;378(6559):789-792.
3. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117-1130.
4. Antoniou AC, Cunningham AP, Peto J, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer. 2008;98(8):1457-1466.
5. Begg CB, Haile RW, Borg A, et al. Variation of breast cancer risk among BRCA1/2 carriers. JAMA. 2008;299(2):194-201.
6. Chen S, Iversen ES, Friebel T, et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol. 2006; 24(6):863-871.
7. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and pene-trance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62(3): 676-689.
8. Hopper JL, Southey MC, Dite GS, et al. Population-based estimate of the average age-specifc cumulative risk of breast cancer for a defned set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev. 1999;8(9):741-747.
9. Milne RL, Osorio A, Cajal TR, et al. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. Clin Cancer Res. 2008; 14(9):2861-2869.
10. Simchoni S, Friedman E, Kaufman B, et al. Familial clustering of site-specifc cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population. Proc Natl Acad Sci USA. 2006;103(10): 3770-3774.
11. Struewing JP, Hartge P, Wacholder S. The risk of cancer associated with specifc mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336(20):1401-1408.
12. Thompson D, Easton D; Breast Cancer Linkage Consortium. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet. 2001;68(2):410-419.
13. Thompson D, Easton D; Breast Cancer Linkage Consortium. Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev. 2002;11(4):329-336. (Pubitemid 34408211)
14. Gayther SA, Warren W, Mazoyer S, et al. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet. 1995;11(4):428-433.
15. Gayther SA, Mangion J, Russell P, et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet. 1997;15(1):103-105.
16. Lubinski J, Phelan CM, Ghadirian P, et al. Cancer variation associated with the position of the mutation in the BRCA2 gene. Fam Cancer. 2004;3(1):1-10.
17. Easton DF, Eeles RA. Genome-wide association studies in cancer. Hum Mol Genet. 2008;17(R2):R109-R115.
18. McCarthy MI, Hirschhorn JN. Genome-wide association studies: past, present and future. Hum Mol Genet. 2008;17(R2):R100-R101.
19. Song H, Ramus SJ, Tyrer J, et al. A genome-wide association study iden-tifes a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet. 2009;41(9):996-1000.
20. Antoniou AC, Spurdle AB, Sinilnikova OM, et al. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet. 2008;82(4):937-948.
21. Antoniou AC, Sinilnikova OM, McGuffog L, et al. Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet. 2009;18(22):4442-4456.
22. Jakubowska A, Rozkrut D, Antoniou A, Hamann U, Lubinski J. The Leu33Pro polymorphism in the ITGB3 gene does not modify BRCA1/2-associated breast or ovarian cancer risks: results from a multicenter study among 15,542 BRCA1 and BRCA2 mutation carriers [published online ahead of print October 30, 2009]. Breast Cancer Res Treat. 2009;121(3):639-649.
23. Rebbeck TR, Mitra N, Domchek SM, et al. Modifcation of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. Cancer Res. 2009;69(14):5801-5810.
24. Chenevix-Trench G, Milne RL, Antoniou AC, et al. An international initiative to identify genetic modifers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifers of BRCA1 and BRCA2 (CIMBA). Breast Cancer Res. 2007;9(2):104.
25. Antoniou AC, Sinilnikova OM, Simard J, et al. RAD51 135G->C modifes breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet. 2007;81(6):1186-1200.
26. Antoniou AC, Goldgar DE, Andrieu N, et al. A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. Genet Epidemiol. 2005;29(1):1-11.
27. Lange K, Weeks D, Boehnke M. Programs for pedigree analysis: MENDEL, FISHER, and dGENE. Genet Epidemiol. 1988;5(6):471-472.
28. Huber PJ. The behavior of maximum likelihood estimates under non-standard conditions. Proc Fifth Berkeley Symp Math Stat Probab. 1967;1: 221-233.
29. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifes novel breast cancer susceptibility loci. Nature. 2007; 447(7148):1087-1093.
30. Hunter DJ, Kraft P, Jacobs KB, et al. A genome-wide association study identifes alleles in FGFR2 associated with risk of sporadic postmeno-pausal breast cancer. Nat Genet. 2007;39(7):870-874.
31. Gold B, Kirchhoff T, Stefanov S, et al. Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc Natl Acad Sci USA. 2008;105(11):4340-4345.
32. Ahmed S, Thomas G, Ghoussaini M, et al. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet. 2009;41(5):585-590.
33. Thomas G, Jacobs KB, Kraft P, et al. A multistage genome-wide association study in breast cancer identifes two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet. 2009;41(5):579-584.
34. Turnbull C, Ahmed S, Morrison J, et al. Genome-wide association study identifes fve new breast cancer susceptibility loci. Nat Genet. 2010;42(6): 504-507.
35. Vanhoutteghem A, Djian P. Basonuclin 2: an extremely conserved ho-molog of the zinc fnger protein basonuclin. Proc Natl Acad Sci USA. 2004;101(10):3468-3473.
36. Vanhoutteghem A, Djian P. Basonuclins 1 and 2, whose genes share a common origin, are proteins with widely different properties and functions. Proc Natl Acad Sci USA. 2006;103(33):12423-12428.
37. Vanhoutteghem A, Djian P. The human basonuclin 2 gene has the potential to generate nearly 90,000 mRNA isoforms encoding over 2000 different proteins. Genomics. 2007;89(1):44-58.
38. Akagi T, Ito T, Kato M, et al. Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esoph-ageal adenocarcinoma. Int J Cancer. 2009;125(10):2349-2359.
39. Romano RA, Li H, Tummala R, Maul R. Identifcation of basonuclin2, a DNA-binding zinc-fnger protein expressed in germ tissues and skin kera-tinocytes. Genomics. 2004;83(5):821-833.
40. Goode EL, Chenevix-Trench G, Song H, et al. A genome-wide association study identifes susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet. 2010;42(10):874-879.
41. Bolton K, Tyrer J, Song H, et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet. 2010;42(10):880-884.
42. Lux MP, Fasching PA, Beckmann MW. Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med. 2006;84(1):16-28.
43. Evans DG, Lalloo F, Ashcroft L, et al. Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent. Cancer Epidemiol Biomarkers Prev. 2009;18(8):2318-2324.